NLS Pharmaceutics (NLSP) News Today $3.29 +0.11 (+3.46%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period NLS Pharmaceutics AG Announces Share Capital ExpansionNovember 16, 2024 | markets.businessinsider.comKadimastem Ltd. Faces Financial UncertaintyNovember 13, 2024 | markets.businessinsider.comNLS Pharmaceutics Announces Strategic Capital RestructuringNovember 7, 2024 | markets.businessinsider.comNLS Pharmaceutics and Kadimastem Announce Strategic MergerNovember 6, 2024 | markets.businessinsider.comNLS Pharmaceutics (NASDAQ:NLSP) Stock, Short Interest ReportNovember 4, 2024 | benzinga.comNLS Pharmaceutics, Kadimastem enter definitive merger agreementNovember 4, 2024 | markets.businessinsider.comNLS Pharmaceutics Merges with Kadimastem for Strategic GrowthNovember 4, 2024 | markets.businessinsider.comWhat's Going On With NLS Pharmaceutics Shares Monday?November 4, 2024 | msn.comNLS Pharmaceutics stock jumps 50% on merger agreement with cell therapy firm KadimastemNovember 4, 2024 | msn.comNLS Pharmaceutics Achieves Nasdaq Compliance MilestoneOctober 29, 2024 | markets.businessinsider.comNLS Pharmaceutics regains full compliance with Nasdaq listing rulesOctober 29, 2024 | markets.businessinsider.comNLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing RequirementsOctober 28, 2024 | finance.yahoo.comNLS Pharmaceutics secures patent in Japan for Mazindol EROctober 22, 2024 | markets.businessinsider.comNLS Pharmaceutics Sees Reduced Losses Amid Financial ChallengesOctober 20, 2024 | finance.yahoo.comWhy Is NLS Pharmaceutics (NLSP) Stock Up 48% Today?July 29, 2024 | investorplace.comNLS Pharmaceutics to Absorb Kadimastem as Subsidiary After Agreeing to MergerJuly 29, 2024 | marketwatch.comKadimastem To Become Subsidiary Of NLS; Kadimastem Shareholders To Hold 85% Of Merged Company SharesJuly 29, 2024 | markets.businessinsider.comNLSP NLS Pharmaceutics AGJuly 26, 2024 | seekingalpha.comWhy Is NLS Pharmaceutics (NLSP) Stock Down 23% Today?June 20, 2024 | investorplace.comWhy Is NLS Pharmaceutics (NLSP) Stock Up 163% Today?June 18, 2024 | investorplace.comNLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol's Neuroprotective Effects in Narcoleptic-like Rat ModelMay 28, 2024 | stockhouse.comNLS Pharmaceutics AG: NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from NasdaqMay 24, 2024 | finanznachrichten.deNLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from NasdaqMay 24, 2024 | finance.yahoo.comNLS Pharmaceutics AG: NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct OfferingMarch 22, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist PlatformMarch 20, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics Announces $1.75 Million Registered Direct OfferingMarch 20, 2024 | finanznachrichten.deNLS Pharmaceutics AG: NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering EventMarch 14, 2024 | finanznachrichten.deNLS Pharmaceutics AG: Nasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing ComplianceMarch 11, 2024 | finanznachrichten.deNasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing ComplianceMarch 11, 2024 | finance.yahoo.comNLS Pharmaceutics AG: NLS Pharmaceutics Submits Plan to Regain Listing Compliance With NasdaqFebruary 23, 2024 | finanznachrichten.deNLSP NLS Pharmaceutics Ltd.February 14, 2024 | seekingalpha.comNotice of Deficiency with Nasdaq Continued Listing RequirementsJanuary 20, 2024 | finance.yahoo.comNLS Pharmaceutics AG: Notice of Deficiency with Nasdaq Continued Listing RequirementsJanuary 12, 2024 | finanznachrichten.deNLS Pharmaceutics Stock (NASDAQ:NLSP) Insider TradesDecember 23, 2023 | benzinga.comNLS Pharmaceutics Ltd Ordinary SharesDecember 21, 2023 | morningstar.comNLS Pharmaceutics Stock (NASDAQ:NLSP) Dividends: History, Yield and DatesDecember 5, 2023 | benzinga.comNLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.December 1, 2023 | finance.yahoo.comNLS Pharmaceutics AG: NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic HypersomniaNovember 27, 2023 | finanznachrichten.deNLS Pharmaceutics Ltd Ordinary Shares NLSPNovember 21, 2023 | morningstar.comWhy NLS Pharmaceutics (NLSP) Stock Is Down 40% TodayNovember 16, 2023 | msn.comNLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge LoanNovember 16, 2023 | finance.yahoo.comNLS Pharmaceuticals to Reschedule Company Update on Strategic DiscussionsOctober 19, 2023 | finance.yahoo.comNLS Pharmaceutics AG: NLS Pharmaceutics Announces Company Update on Strategic PartnershipsOctober 12, 2023 | finanznachrichten.deNLS Pharmaceutics Announces Company Update on Strategic PartnershipsOctober 12, 2023 | finance.yahoo.comNLS Pharmaceutics (NLSP) Price Target Increased by 24.47% to 9.95October 5, 2023 | msn.comMaxim Group Downgrades NLS Pharmaceutics (NLSP)September 14, 2023 | msn.comNLS Pharmaceutics CEO Highlights Progress And Plans For Advancing Rare CNS Disorder Therapies In Shareholder LetterAugust 28, 2023 | benzinga.comNLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study ProtocolJuly 3, 2023 | finance.yahoo.comNLS Pharmaceutics AG: NLS Pharmaceutics Company Update and Webcast Today PostponedJuly 2, 2023 | finanznachrichten.deNLS Pharmaceutics Releases the Results from its Annual General MeetingJune 30, 2023 | finance.yahoo.com Get NLS Pharmaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter. Email Address Bill Gates’s Next Big AI Bet: Stargate (Ad)In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then. I believe we are about to do it again with this new AI project called Stargate NLSP Media Mentions By Week NLSP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NLSP News Sentiment▼0.200.46▲Average Medical News Sentiment NLSP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NLSP Articles This Week▼10▲NLSP Articles Average Week Get NLS Pharmaceutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NLSP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Exicure News Affimed News Protara Therapeutics News DBV Technologies News Atlantic Coastal Acquisition Corp. II News Immix Biopharma News Gain Therapeutics News CalciMedica News SCYNEXIS News Actinium Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NLSP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
